# A Study of Tadalafil for Duchenne Muscular Dystrophy

> **NCT01865084** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 331 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01865084
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 331 (ACTUAL)
- **Why stopped:** The study is being terminated for lack of efficacy
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865084, "A Study of Tadalafil for Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01865084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*